Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds

Abstract

Currently, it is estimated that 1–2 million people worldwide are infected with HIV-2, accounting for 3–5% of the global burden of HIV. The course of HIV-2 infection is longer compared to HIV-1 infection, but without effective antiretroviral therapy (ART), a substantial proportion of infected patients will progress to AIDS and die. Antiretroviral drugs in clinical use were designed for HIV-1 and, unfortunately, some do not work as well, or do not work at all, for HIV-2. This is the case for non-nucleoside reverse transcriptase inhibitors (NNRTIs), the fusion inhibitor enfuvirtide (T-20), most protease inhibitors (PIs), the attachment inhibitor fostemsavir and most broadly neutralizing antibodies. Integrase inhibitors work well against HIV-2 and are included in first-line therapeutic regimens for HIV-2-infected patients. However, rapid emergence of drug resistance and cross-resistance within each drug class dramatically reduces second-line treatment options. New drugs are needed to treat infection with drug-resistant isolates. Here, we review the therapeutic armamentarium available to treat HIV-2-infected patients, as well as promising drugs in development. We also review HIV-2 drug resistance mutations and resistance pathways that develop in HIV-2-infected patients under treatment.

Honey as a Natural Nutraceutical: Its Combinational Therapeutic Strategies Applicable to Blood Infections—Septicemia, HIV, SARS-CoV-2, Malaria

“…If left untreated, within eight to ten years after exposure, the infection will progress to AIDS, and may manifest as chronic diarrhea, chronic fatigue, skin rash and irritation development, lesions, ulcers, and white spotting of the tongue and mouth, and recurring and persistent fever [ 58 ]. The HIV virus is categorized between HIV Type 1 (HIV-1) and HIV Type 2 (HIV-2), each with separate further subtypes, and it is recommended and accepted to give an immediate prescription of an antiretroviral regime after diagnosis of infection [ 59 , 60 , 61 ].…”

Evidence for Mother-to-Child Transmission of HIV-2 in Uganda: A Retrospective Analysis

“…[3] HIV-2 accounts for 3 to 5% of the global HIV burden, with current estimates suggesting approximately 1-2 million infected individuals worldwide. [4] The highest prevalence rates of HIV-2 in the world were known be recorded in parts of populations in West African countries. [5, 6] Within Europe, France and Portugal have reported the highest prevalence rates of HIV-2 infection, with approximately 1000 and 2000 cases recorded in each country, respectively.…”

Quality assessment of oral antimalarial and antiretroviral medicines used by public health systems in Sahel countries

“…Type 2 is more prevalent in Africa and has an intrinsic resistance to non-nucleoside reverse transcriptase inhibitors and fusion inhibitors as well as higher variability in the response against protease inhibitors [ 10 ]. Therefore, the most common APIs used against HIV-2 are a combination of 2 nucleoside reverse transcriptase inhibitors (ABC/3TC) and 2 protease inhibitors (LPV/RTV, officially the medicine is abbreviated as LPV/r) [ 11 ].…”